Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries

Table 2 Screening accuracy of the 5–2-1 screening criteria in identifying patients with advanced Parkinson’s disease

	Advanced PD		Adjusted Model ^a
Indicator	No	Yes	OR (95% CI)	Correct Classification (%) ^b	AUC ^c
5–2-1 screening criteria
Negative	3018	150	1	–	–
Positive	994	552	6.84 (5.50, 8.51)	88.1	0.89
Individual clinical indicators
≥2 h off-time/day
Negative	3299	208	1	–	–
Positive	713	494	7.07 (5.76, 8.68)	88.4	0.89
≥1 h troublesome dyskinesia/day
Negative	3944	591	1	–	–
Positive	68	111	5.56 (3.85, 8.02)	87.1	0.85
≥5 doses of oral levodopa/day
Negative	3501	413	1	–	–
Positive	511	289	3.03 (2.45, 3.73)	87.1	0.86

^aRegressions adjusted for age, sex, time since diagnosis, Charlson Comorbidity Index, and country. ^bCorrect classification is the percentage of patients correctly classified per 5–2-1 criteria (sum of true positive and true negatives divided by total number of patients). ^C AUC is a screening accuracy measure that balances sensitivity and specificity. AUC is interpreted as follows: AUC = 0.5, non-informative; AUC = 0.5 to ≤0.7, less accurate; AUC = 0.7 to ≤0.9, moderately accurate, AUC 0.9 to < 1, highly accurate; AUC = 1, perfect test [27,28,29]
AUC Area under the curve, CI Confidence interval, OR Odds ratio

ISSN: 1471-2377